ICPT - Intercept Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
104.73
-2.89 (-2.69%)
At close: 4:00PM EDT

104.95 +0.22 (0.21%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close107.62
Open107.24
Bid103.00 x 1000
Ask106.00 x 1000
Day's Range103.52 - 107.24
52 Week Range51.05 - 133.74
Volume318,244
Avg. Volume485,126
Market Cap3.096B
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-13.00
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est134.60
Trade prices are not sourced from all markets
  • 5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage
    InvestorPlace9 hours ago

    5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage

    For whatever the reason — the trade war, Federal Reserve or general market malaise — investors have turned on a variety high-momentum shares. The rout in biotech stocks has been pretty severe. The iShares NASDAQ Biotechnology Index (NYSEARCA:IBB) — the broad sector benchmark — is down roughly 5% in October.

  • Can This Tiny Biotech Revolutionize a $35 Billion Market?
    Motley Foolyesterday

    Can This Tiny Biotech Revolutionize a $35 Billion Market?

    This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.

  • Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock
    Motley Fool2 days ago

    Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock

    Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPT

  • Why Intercept Pharmaceuticals, Inc. Stock Raced Higher in September
    Motley Fool7 days ago

    Why Intercept Pharmaceuticals, Inc. Stock Raced Higher in September

    Intercept kept rising last month, thanks to Wall Street's change of heart.

  • Analysts Remain Bullish on Intercept Pharmaceuticals
    Market Realist14 days ago

    Analysts Remain Bullish on Intercept Pharmaceuticals

    In October, of the 17 analysts covering Intercept Pharmaceuticals (ICPT), eight have given the stock “buy” or higher ratings, and eight have given it “hold” ratings. One analyst has given Intercept a “sell.” 

  • A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline
    Market Realist14 days ago

    A Look at Intercept Pharmaceuticals’ Exciting Research Pipeline

    Nonalcoholic steatohepatitis (or NASH) focused stocks have been garnering more investor interest so far in 2018. In this series, we’ll analyze three companies with focused NASH pipelines: Intercept Pharmaceuticals (ICPT), Viking Therapeutics (VKTX), and Madrigal Pharmaceuticals (MDGL).

  • Investopedia21 days ago

    3 Biotechs Poised for 10% Gains

    Technical analysis suggests that Acadia Pharmaceuticals Inc. ( ACAD), BeiGene Ltd. ( BGNE) and Intercept Pharmaceuticals Inc. ( ICPT) are three such stocks that could see the significant gains. Acadia shares have skyrocketed higher over the past few weeks and are trading around a technical resistance level at $21.50. Should the stock be able to rise above that level of resistance, the shares could rally by 13% to a price of $24, from its current price of around $21.40.

  • GlobeNewswire22 days ago

    Intercept to Present at Upcoming Investor Conference

    NEW YORK, Sept. 26, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Intercept Pharmaceuticals Inc NASDAQ/NGS:ICPT

  • What Spark Therapeutics’ Valuation Trend Indicates
    Market Realistlast month

    What Spark Therapeutics’ Valuation Trend Indicates

    Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Short interest is moderate for ICPT with between 5 and 10% of shares outstanding currently on loan. The $1.27 billion in inflows that ETFs holding ICPT received over the last one-month is a decline from earlier in the period and among the weakest of the past year.

  • Analyzing Axovant Sciences’ Valuation Metrics
    Market Realistlast month

    Analyzing Axovant Sciences’ Valuation Metrics

    In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.

  • 3 Top Stocks for Investing in Pharma's Next $35 Billion Market
    Motley Foollast month

    3 Top Stocks for Investing in Pharma's Next $35 Billion Market

    Here's why these three biotechs could come out ahead in the race to tackle a leading cause of liver failure.

  • Here's Why Intercept Pharmaceuticals Jumped 22.7% in August
    Motley Foollast month

    Here's Why Intercept Pharmaceuticals Jumped 22.7% in August

    Its Ocaliva is selling well enough as investors wait for more clinical trial data next year.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Intercept Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Wall Street plunged on Friday after the Trump administration announced tariffs on another $267 billion worth of Chinese goods, pressuring the S&P 500 and ...

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on September 5.

  • GlobeNewswire2 months ago

    Intercept to Present at Upcoming Investor Conferences

    NEW YORK, Aug. 29, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...

  • See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Intercept Pharmaceuticals Inc.

    Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Array BioPharma and Intercept Pharmaceuticals

    On Friday, Fed Chairman Jerome Powell is scheduled for a speech at the Kansas City Fed’s annual summer retreat. The Nasdaq Composite Index increased 0.49 percent to close at 7,859.17. Investment strategist at Edward Jones, Kate Warne said, “I think that this is optimism on at least some partial resolution of the trade negotiations as investors are expecting progress [on that front].” “If we reach new highs that’s great but I think it would be a reflection of the positive underlying fundamentals of very positive earnings growth and modest interest rates,” Warne added.

  • Array BioPharma Posted Net Loss of $52.4 Million in Q4
    Market Realist2 months ago

    Array BioPharma Posted Net Loss of $52.4 Million in Q4

    On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.

  • Is Intercept Pharmaceuticals, Inc. a Buy?
    Motley Fool2 months ago

    Is Intercept Pharmaceuticals, Inc. a Buy?

    This company's leading a race that's drawn a lot of competition.

  • What Analysts Recommend for Array BioPharma Stock
    Market Realist2 months ago

    What Analysts Recommend for Array BioPharma Stock

    Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ICPT earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Intercept Pharmaceuticals Inc Earnings Call

  • Investopedia2 months ago

    4 Biotech Stocks That May Fall By as Much as 13%

    Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.